Concord Biotech Limited - Asset Resilience Ratio

Latest as of September 2025: 18.00%

Concord Biotech Limited (CONCORDBIO) has an Asset Resilience Ratio of 18.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Concord Biotech Limited (CONCORDBIO) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Rs3.64 Billion

≈ $39.38 Million USD Cash + Short-term Investments

Total Assets

Rs20.23 Billion

≈ $218.80 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2020–2025)

This chart shows how Concord Biotech Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Concord Biotech Limited asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Concord Biotech Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read CONCORDBIO liabilities breakdown for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs3.64 Billion	18.0%
Total Liquid Assets	Rs3.64 Billion	18.00%

Asset Resilience Insights

Good Liquidity Position: Concord Biotech Limited maintains a healthy 18.00% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Concord Biotech Limited Industry Peers by Asset Resilience Ratio

Compare Concord Biotech Limited's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Concord Biotech Limited (2020–2025)

The table below shows the annual Asset Resilience Ratio data for Concord Biotech Limited.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	15.56%	Rs3.17 Billion ≈ $34.23 Million	Rs20.34 Billion ≈ $220.00 Million	-0.34pp
2024-03-31	15.90%	Rs2.70 Billion ≈ $29.24 Million	Rs17.01 Billion ≈ $183.93 Million	+4.17pp
2023-03-31	11.73%	Rs1.78 Billion ≈ $19.21 Million	Rs15.14 Billion ≈ $163.73 Million	-0.54pp
2022-03-31	12.27%	Rs1.61 Billion ≈ $17.42 Million	Rs13.13 Billion ≈ $141.97 Million	-4.31pp
2021-03-31	16.58%	Rs1.96 Billion ≈ $21.20 Million	Rs11.83 Billion ≈ $127.89 Million	-4.48pp
2020-03-31	21.06%	Rs1.98 Billion ≈ $21.42 Million	Rs9.41 Billion ≈ $101.71 Million	--

pp = percentage points

About Concord Biotech Limited

NSE:CONCORDBIO India Biotechnology

Market Cap

$1.69 Billion

Rs156.34 Billion INR

Market Cap Rank

#6826 Global

#322 in India

Share Price

Rs1494.40

Change (1 day)

+2.28%

52-Week Range

Rs1014.80 - Rs1647.70

All Time High

Rs2601.10